Literature DB >> 11030016

Overview of the angiotensin-converting-enzyme inhibitors.

R W Piepho1.   

Abstract

The pharmacology of angiotensin-converting-enzyme (ACE) inhibitors and their role in the renin-angiotensin system (RAS) are described, and pharmacokinetic properties and common adverse events are presented. ACE inhibitors play a vital role in the RAS by regulating the potent vasoconstrictor angiotensin II. All ACE inhibitors share the same basic structure; however, they can be separated on the basis of their functional (binding) group: carboxyl, sulfhydryl, or phosphinyl. These functional groups are, in part, responsible for differences in the pharmacokinetic and safety profiles of these agents. Captopril and lisinopril are the only ACE inhibitors that are not prodrugs requiring activation through hepatic biotransformation. Differences among the ACE inhibitors in lipophilicity are described; fosinopril has the greatest lipophilicity and lisinopril the least. ACE is found in numerous tissues, and there is increasing evidence of differences among ACE inhibitors in their ability to inhibit tissue ACE. Most ACE inhibitors are eliminated mainly by the kidneys and to a lesser extent through the liver. Lisinopril is the only ACE inhibitor that does not require hepatic metabolism. In the selection of an ACE inhibitor for once-daily use to treat hypertension, differences in trough-peak ratios are clinically relevant. Fosinopril, ramipril, and trandolapril have minimum trough-peak ratios of 50% or greater. ACE inhibitors are generally well tolerated, with hypotension, cough, and hyperkalemia being the most frequently reported adverse effects for the entire class. Drug interactions across the ACE inhibitor class as well as agent-specific interactions are described. Factors to be considered in the selection of an ACE inhibitor include differences in potency, affinity for ACE, pharmacokinetics, and toxicity that are related to structural properties of the drug; whether the trough-peak ratio enables use of a once-daily dose; and potential adverse effects related to a drug's functional (binding) group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11030016     DOI: 10.1093/ajhp/57.suppl_1.S3

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  14 in total

1.  ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

Authors:  Matteo Cesari; Claudio Pedone; Raffaele Antonelli Incalzi; Marco Pahor
Journal:  J Am Med Dir Assoc       Date:  2009-11-25       Impact factor: 4.669

2.  Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

Authors:  Matteo Cesari; Stephen B Kritchevsky; Hal H Atkinson; Brenda W Penninx; Mauro Di Bari; Russell P Tracy; Marco Pahor
Journal:  Am Heart J       Date:  2009-02       Impact factor: 4.749

3.  Protective effect of lisinopril on hepatic ischemia/reperfusion injury in rats.

Authors:  M A Morsy
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

4.  Zofenopril and incidence of cough: a review of published and unpublished data.

Authors:  Stefano Omboni; Claudio Borghi
Journal:  Ther Clin Risk Manag       Date:  2011-11-29       Impact factor: 2.423

Review 5.  Antihypertensive Peptides from Milk Proteins.

Authors:  Pauliina Jäkälä; Heikki Vapaatalo
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-19

6.  Meta-path Based Prioritization of Functional Drug Actions with Multi-Level Biological Networks.

Authors:  Seyeol Yoon; Doheon Lee
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

7.  Impaired metabolic effects of metformin in men with early-onset androgenic alopecia.

Authors:  Robert Krysiak; Karolina Kowalcze; Bogusław Okopień
Journal:  Pharmacol Rep       Date:  2021-12-12       Impact factor: 3.024

8.  VPPIPP and IPPVPP: two hexapeptides innovated to exert antihypertensive activity.

Authors:  Fengyun Ding; Bingjun Qian; Xin Zhao; Shanqi Shen; Yun Deng; Danfeng Wang; Feng Zhang; Zhongquan Sui; Pu Jing
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats.

Authors:  Nora Hegazy; Samar Rezq; Ahmed Fahmy
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

10.  Use of a data warehouse at an academic medical center for clinical pathology quality improvement, education, and research.

Authors:  Matthew D Krasowski; Andy Schriever; Gagan Mathur; John L Blau; Stephanie L Stauffer; Bradley A Ford
Journal:  J Pathol Inform       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.